Overview


According to FutureWise analysis the market for intravitreal (ivt) injectables in 2023 is US$ 15.7 billion, and is expected to reach US$ 27 billion by 2031 at a CAGR of 6.5%.

Intravitreal injection is the process of injecting drugs into the eyeball using a fine needle. These medications will then be administered directly to the vitreous humour. This medication can treat some eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye, such as endophthalmitis. When compared to topical administration, this method allows for more targeted medication delivery because the needle can pass directly through the anatomical (e.g., cornea, conjunctiva, and lens) and dynamic barriers (e.g., tears and aqueous humour). It may also reduce adverse drug effects to other body tissues via systemic circulation, which may be a risk with intravenous medication injection.

Wet age-related macular degeneration (AMD) causes vision loss because new, aberrant, leaky blood vessels begin to invade the retina, filling it with extra fluid and causing it to enlarge. A molecule known as VEGF, or vascular endothelial growth factor, is one of the key initiators of this blood vessel expansion. Many medications that prevent the activity of VEGF have been created over the past 15 years, lowering swelling, at least partially recovering eyesight, or maintaining the course of the disease. Anti-VEGF medications must be injected into the eye because they are big molecules and cannot be taken orally or used as eyedrops to achieve the desired effects. Intravitreal (IVT) injections are used to provide the medication because they are injected into the vitreous, which is located in front of the retina.

FutureWise Market Research has published a report that provides an insightful analysis of intravitreal (IVT) injectables market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the intravitreal (IVT) injectables market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Alcon Pharmaceuticals
  • Novartis
  • Regeneron Pharmaceuticals Inc.
  • Allergan
  • Alimera Sciences
  • Bristol Myers Squibb
  • Bausch And Lomb
  • F. Hoffmann-La Roche
  • Thrombogenics
  • Valeant Pharmaceuticals International

(Note: The list of the major players will be updated with the latest market scenario and trends)

The global prevalence of retinal diseases such as age-related muscular degeneration, retinal occlusions, and diabetic retinopathy is rising, fuelling the global intravitreal injectables market. Furthermore, the development of anti-vascular endothelial growth factor (anti-VEGF) injections has the potential to extend functional visual acuity in an additional 20% of patients for the rest of their natural lives. Because intravitreal injectables effectively treat retinal problems and are widely used to treat intraocular diseases, the intravitreal injectables market is expected to grow rapidly during the forecast period. There are currently several anti-VEGF drugs on the market, including pegaptanib, ranibizumab, bevacizumab, and aflibercept. Despite the fact that well-designed clinical trials have demonstrated that these agents improve vision in a variety of retinal diseases, each intravitreal injection carries the risk of post-injection and drug-class-related adverse events. The requirement for multiple and long-term injections may increase the risk of ocular and systemic complications. As a result, the post-infections caused by the intravitreal injections are expected to limit the intravitreal injectables market. Favourable regulatory guidelines for designing and manufacturing intravitreal injectables for patient safety will drive market growth. Manufacturers are working to develop intravitreal injectables that meet these regulatory requirements. Furthermore, with a strong pipeline of IVT injections for the treatment of retinal conditions, an increased industry focus on innovation is expected to propel the intravitreal market, providing opportunities for key players in the target market. The use of the disposable device over the conventional method of injectables has increased among individuals due to advantages like less pain score and also a reduction in device cost and manpower. The innovation and development in the device of intravitreal injection are expected to boost the revenue of this target market.

By Drug Class

  • Anti-VEGF
  • Antibiotics
  • Corticosteroids
  • Antifungals
  • Antivirals

By Indication

  • Diabetic Retinopathy
  • Macular Degeneration
  • Endophthalmitis
  • Retinal Vein Occlusions

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The demand for intravitreal (IVT) injectables in North America is predicted to increase as age-related macular degeneration (AMD) becomes more common. Furthermore, due to a favourable reimbursement environment, intravitreal injections are the most frequent ophthalmic operation performed in the nation. This is projected to support market expansion in the coming years. The demand for intravitreal (IVT) injectables in the area is expected to increase because of the ageing population and the burden of retinal illnesses in the region. Besides that, based on drug type; anti-VEGF holds majority share in global market with 91.8% in 2022.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Intravitreal (IVT) Injectables Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Intravitreal (IVT) Injectables Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Intravitreal (IVT) Injectables Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Intravitreal (IVT) Injectables Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anti-VEGF
        2. Antibiotics
        3. Corticosteroids
        4. Antifungals
        5. Antivirals

  • 8.   Global Intravitreal (IVT) Injectables Market, By Indication Historical Analysis and Forecast 2023-2031(USD Million)
    •   1. Diabetic Retinopathy
        2. Macular Degeneration
        3. Endophthalmitis
        4. Retinal Vein Occlusions

  • 9.   Global Intravitreal (IVT) Injectables Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Drug Stores
        4. Online Pharmacies

  • 10.   North America Intravitreal (IVT) Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Intravitreal (IVT) Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Intravitreal (IVT) Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Intravitreal (IVT) Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)
    •   1. Alcon Pharmaceuticals
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Regeneron Pharmaceuticals Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Alimera Sciences
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol Myers Squibb
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bausch And Lomb
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. F. Hoffmann-La Roche
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Thrombogenics
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Valeant Pharmaceuticals International
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients